Analysis of the specificity and kinetics of neutralizing antibodies (nAbs) elicited by SARS-CoV-2
infection is crucial for understanding immune protection and identifying targets for …

Transmission of SARS-CoV-2 is uncontrolled in many parts of the world; control is compounded
in some areas by the higher transmission potential of the B.1.1.7 variant 1 , which has …

A novel variant of concern (VOC) named CAL.20C (B.1.427/B.1.429), which was originally
detected in California, carries spike glycoprotein mutations S13I in the signal peptide, W152C …

An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape 1 , 2 – 3 , have
activity against diverse sarbecoviruses 4 , 5 , 6 – 7 , and be highly protective through viral …

The recently emerged SARS-CoV-2 Omicron variant encodes 37 amino acid substitutions in
the spike protein, 15 of which are in the receptor-binding domain (RBD), thereby raising …

The spillovers of betacoronaviruses in humans and the emergence of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants highlight the need for broad coronavirus …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry
distinct spike mutations resulting in escape from antibodies induced by previous infection or …

The SARS-CoV-2 spike (S) glycoprotein contains an immunodominant receptor-binding
domain (RBD) targeted by most neutralizing antibodies (Abs) in COVID-19 patient plasma. Little …

The recent emergence of SARS-CoV-2 variants of concern 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 – 10
and the recurrent spillovers of coronaviruses 11 , 12 into the human population highlight the …

Currently circulating SARS-CoV-2 variants have acquired convergent mutations at hot spots
in the receptor-binding domain 1 (RBD) of the spike protein. The effects of these mutations …